


Figure 1

1A.



1B.



1C.





Figure 2


2A.



2C.

09761101101

2B.



2



3



der(2)



der(3)

Figure 3

3 A. PAX8-PPAR γ STRUCTURE:


PD	HD	A/B	C	D	E/F
PAX8 DNA BINDING DOMAINS		PPAR γ NUCLEAR RECEPTOR DOMAINS			

PAX8e7-PPAR γ e1: AGA CCT ACC CCG TGG TGG CAG -- AAA TGA CCA TGG TTG ACA CAG

PAX8e8-PPAR γ e1: CGG GCC AGG CCC TCC TCT CAG -- AAA TGA CCA TGG TTG ACA CAG

PAX8e9-PPAR γ e1: CCA TCG CAG GCA TGG TGG CAG -- AAA TGA CCA TGG TTG ACA CAG

3 B. PAX8-PPAR γ mRNA:



3 C. PAX8-PPAR γ PROTEIN:






Figure 4

4A. PAX8-PPAR γ RTPCR:




097511.01100
FOETD" T159260

4B. PAX8-PPAR γ IMMUNOHISTOCHEMISTRY:



anti-PPAR γ




anti-PPAR γ
+ PPAR γ peptide


4C.

THYROID NEOPLASM	RT-PCR	IMH
Follicular Carcinoma	5/8	7/8
Follicular Adenoma	0/20	0/20
Papillary Carcinoma	0/10	0/10
Multi-nodular Hyperplasia	0/10	0/10

THYROID FOLLICULAR CARCINOMA: t(2;3)(q13;p25)---->PAX8-PPAR γ



ACUTE PROMYELOCYTIC LEUKEMIA: t(15;17)(q22;q11-21) ----->PML-RAR α



ALVEOLAR RHABDOMYOSARCOMA: t(2;13)(q35;q14) ----->PAX3-FKHR





Figure 5

Figure 6

6 A.



6 B.

